Idogen announces that the United States Patent & Trademark Office has issued a “Notice of Allowance”, which means that it intends to grant Idogen’s patent application.
The United States Patent & Trademark Office (USPTO) has communicated its intention to grant Idogen’s Patent Application No. 14/553,098. The patent belongs to Idogen’s second patent family and covers Idogen’s technology for induction of IDO for treatment of autoimmune diseases and transplant rejection. Once the issue fee is paid by Idogen and necessary formalities have been completed by the USPTO, the patent will be granted. The patent term will then extend to December 2031, potentially longer if adjustment is made for any delays in the processing at the patent office. The US patent will provide Idogen’s tolerogenic vaccine technology with broad protection in a key market and significantly strengthens the company’s patent portfolio.
”This patent provides very important protection for our tolerogenic vaccine platform in the USA. This is a key market representing 40% of the global pharmaceutical market and is important territory for innovative therapies such as ours. The decision that the USPTO will grant a patent gives us great encouragement,” said Lars Hedbys, CEO of Idogen.
Related applications were granted in Japan and the subject of a “Notice of Intention to Grant” in Europe in January 2017. A further related application is pending in Canada. The granted patent will complement the Japanese granted patent in this family and an earlier European Patent in Idogen’s first patent family, granted in December 2013.